Phase II study of maintenance trifluridine/tipiracil (TAS-102) plus bevacizumab after induction chemotherapy in metastatic colorectal cancer

This strategy of switching to first-line maintenance therapy with TAS+Bev demonstrated promising efficacy and safety. This strategy effectively avoided cumulative neurotoxicity, preserved quality of life and enabled reintroduction of oxaliplatin, suggesting it may represent a promising alternative strategy for patients ineligible for prolonged oxaliplatin-based treatment. Overall survival analysis is currently ongoing. [UMIN Trial ID: UMIN000031317].

Authors

Institutions

Publication Details

Journal
The Oncologist
Published
2026-02-26
DOI
https://doi.org/10.1093/oncolo/oyag067
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Phase II study of maintenance trifluridine/tipiracil (TAS-102) plus bevacizumab after induction chemotherapy in metastatic colorectal cancer

Yujiro Nishizawa, Yoshinori Kagawa, Tsukasa Tanida, Shinji Tokuyama et al.
The Oncologist
Colorectal Cancer Treatments and Studies
article

Phase II study of maintenance trifluridine/tipiracil (TAS-102) plus bevacizumab after induction chemotherapy in metastatic colorectal cancer

Yujiro Nishizawa, Yoshinori Kagawa, Tsukasa Tanida, Shinji Tokuyama, Satoshi Sugimoto, Hiroshi Tamagawa, Naohiro Nishida, Masayuki Hiraki, Takayuki Ogino, Hidetoshi Eguchi, Hidekazu Takahashi, T. Kudo, Terukazu Yoshihara, Mamoru Uemura, Mutsumi Fukunaga, Masayoshi Yasui, Yusuke Matsuura, Ken Nakata, Rei Suzuki, Masakazu Miyake, Naotsugu Haraguchi, Katsuya Ota, Akio Fukada, Kazuya Iwamoto, Koki Tamai, Hirofumi Ota, Atsushi Naito, Yusuke Takahashi, Takamichi Komori, Yuichiro Doki, Nobuo Takiguchi, Soichiro Minami, Mitsuyoshi Tei, Hirofumi Yamamoto, Kohei Murata, Norikatsu Miyoshi, Taroh Satoh
article en

Abstract

This strategy of switching to first-line maintenance therapy with TAS+Bev demonstrated promising efficacy and safety. This strategy effectively avoided cumulative neurotoxicity, preserved quality of life and enabled reintroduction of oxaliplatin, suggesting it may represent a promising alternative strategy for patients ineligible for prolonged oxaliplatin-based treatment. Overall survival analysis is currently ongoing. [UMIN Trial ID: UMIN000031317].

The Oncologist
Tokai University (JP), Osaka City University (JP), Osaka National Hospital (JP), Osaka City General Hospital (JP), Osaka International Cancer Institute (JP), Saiseikaisenri Hospital (JP), Ikeda Municipal Hospital (JP), Sakai Municipal Hospital (JP), Osaka Rosai Hospital (JP), Nara City Hospital (JP), Kansai Rosai Hospital (JP), Higashi Osaka City General Hospital (JP), Osaka Hospital (JP), Izumi City General Hospital (JP), Hyogo Prefectural Nishinomiya Hospital (JP), Otemae Hospital (JP), The University of Osaka (JP)
Good health and well-being
Openalex Percentile: Top 36%
Colorectal Cancer Treatments and Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.